🇨🇭 Swiss Data Privacy & Precision

Unified clinical trial software

Unified clinical trial software for complex oncology trials

oomnia unifies clinical operations for adaptive, data‑intensive oncology trials, helping biotech and mid‑market pharma improve execution and strengthen data quality across global studies

ISO 27001 SOC 2 FDA 21 CFR Part 11 GDPR & HIPAA

INDUSTRY CONTEXT

Why oncology trials are hard to run

Oncology trials are hard to run due to adaptive designs, high data volume, and multi-source data dependencies.

Key challenges include:

Frequent protocol changes driven by complex study designs

High-volume, multi-source data (clinical, imaging, biomarker, safety)

Tight timelines in competitive indications

Global, multi‑center operational complexity

High site burden combined with strict data quality requirements

UNIFIED PLATFORM

Why unified clinical trial software is essential for oncology trials

When oncology trials depend on separate systems to manage clinical data, imaging, biomarker results, safety reporting, and operational workflows, teams encounter fragmented information, slow decision-making, and heavy operational load on sites and study teams. A unified clinical trial platform built as a Clinical Research Information System (CRIS) brings oncology-specific data and processes together within a single, centralized environment designed for complex, data-intensive oncology research.

Why unified clinical trial software is essential for oncology trials
Challenge area Legacy performance oomnia result
Protocol amendment costs Up to $535K Configuration changes in hours
Drug supply overage 200–300% typical Reduced to 30–50%
Database lock delays 50% from non-CRF data reconciliation Removed by design
Query management ~96,980 queries per Phase III Real-time edit checks prevent errors at entry
Site workload 98% Manual re-entry across systems Single interface, single sign-on

This model supports continuous alignment of clinical, imaging, and biomarker data, improves visibility into patient outcomes and safety signals, and enables more efficient execution of multi-arm, multi-site oncology studies.

CRIS ARCHITECTURE

One unified clinical trial platform for oncology trials

oomnia unifies eight separate tools into one clinical research information system (CRIS), giving oncology teams a streamlined framework built for complex, adaptive studies

Purpose-built to support adaptive, biomarker-driven oncology designs within one coordinated environment

Powered by a single data model that keeps clinical, operational, and patient data continuously aligned

Protocol updates are managed through configuration, allowing studies to adjust without system rebuilds

Minimizes handoffs and reduces friction by replacing fragmented systems with one connected workflow

ECOSYSTEM INTEGRATION

How oomnia connects sponsors, data, and sites in oncology trials

oomnia acts as a central clinical data hub connecting all stakeholders across the oncology trial ecosystem

It integrates:

Site electronic health record (EHR) systems
Laboratories
Imaging vendors
Safety and pharmacovigilance systems
Sponsor analytics and reporting environments

KEY CAPABILITIES

Key capabilities for oncology trials

Trial design and adaptation

  • Supports multi‑arm, adaptive, and biomarker‑driven oncology protocols
  • Enables rapid configuration when cohorts expand or protocol amendments occur
  • Minimizes disruption during mid‑study changes and complex schema updates

Data capture and quality

  • Real‑time data entry and validation across high‑volume oncology datasets
  • Unified data flow across EDC, CTMS, RTSM, ePRO/eCOA, eTMF, eSource, and eConsent
  • Reduces manual reconciliation and eliminates duplicate data entry

Patient engagement

  • Flexible ePRO/eCOA for symptom burden, toxicity, and quality‑of‑life reporting
  • Remote and in‑clinic patient data capture to support long, intensive treatment cycles
  • Automated reminders reduce missed assessments and improve visit adherence

Oversight and analytics

  • Real‑time dashboards combining clinical, imaging, laboratory, and biomarker data
  • Supports interim analyses, safety reviews, and decision‑making across global programs
  • Export‑ready outputs for regulatory submissions (FDA, EMA, global authorities)

Imaging and biomarker integration

  • Integrates imaging data flowing from central reading centers into the unified clinical trial software
  • Connects laboratory and biomarker data directly with safety monitoring and analytics
  • Provides a consolidated view of clinical outcomes, imaging, and molecular endpoints

Designed specifically for adaptive, biomarker‑driven oncology research

Built on a single relational architecture rather than layered integrations

Configuration replaces redevelopment when protocols evolve

Reduces operational friction for sites, sponsors, and CROs

Eliminates the need to manage multiple disconnected systems

VALUE PROPOSITION

Why sponsors choose oomnia for oncology trials

LEADERSHIP PERSPECTIVE

What our clients say

The power of trust-driven teams

"Our greatest strength lies in our people. Their collective talent and spirit turn ambitious ideas into real progress for clinical research. Our joint approach to building solutions – thoughtful, data-driven, and rooted in real pain points with a unified vision for how clinical research should work – is what truly sets Wemedoo apart."
Valérie Czaya, MA
Chief Operating Officer, Wemedoo

REGULATORY READINESS

Regulatory and data ecosystem readiness

oomnia provides oncology teams with a compliance‑ready data environment that meets global regulatory expectations

21 CFR Part 11 compliance

21 CFR Part 11‑ready records, complete with audit trails and secure electronic signatures

Risk-Based Quality Management

Risk‑Based Quality Management (ICH E6(R3)) incorporated directly into routine study workflows

CDISC-aligned data standards

CDISC‑aligned data standards, including CDASH for collection and SDTM‑compatible outputs

Global regulatory submissions

Built to support regulatory submissions across FDA, EMA, and global authorities

Get Started

Design your next oncology trial with confidence

Discover how oomnia streamlines complex oncology studies, unifying data, workflows, and teams from first patient in to database lock

Talk to our team

Frequently asked questions

What is unified clinical trial software for oncology trials?

Unified clinical trial software for oncology trials, like oomnia, is a solution that centralizes all study data, workflows, and tools into one clinical research information system (CRIS), replacing disconnected systems and improving execution across complex oncology studies.

Why do oncology trials need a unified clinical research information system (CRIS)?

Oncology trials generate large, multi‑source datasets and undergo frequent protocol adjustments; a unified CRIS ensures consistent data flow, reduces manual reconciliation, and supports real‑time operational oversight across global studies.

How does oomnia support adaptive and biomarker‑driven oncology trial designs?

oomnia enables flexible configuration for multi‑arm, biomarker‑based, and adaptive protocols, allowing teams to update cohorts and study designs without system rebuilds or downtime.

What systems does oomnia unify for oncology trial execution?

oomnia combines electronic data capture (EDC), clinical trial management system (CTMS), randomization and trial supply management (RTSM), electronic patient‑reported outcomes/electronic clinical outcome assessments (ePRO/eCOA), electronic trial master file (eTMF), electronic source data (eSource), and electronic consent (eConsent) into one connected clinical research information system (CRIS), ensuring that all oncology trial data flows through a single, consistent environment.

How does oomnia reduce delays caused by protocol amendments?

By handling study changes through configurable settings instead of redevelopment, oomnia significantly reduces the operational impact of protocol amendments and keeps oncology trials moving forward.

Can oomnia manage the high data volume typical in oncology trials?

Yes. oomnia is designed to manage oncology's data‑intensive workflows, supporting real‑time validation and integrating imaging, lab, and biomarker data into a unified dataset.

How does oomnia improve the site experience in oncology studies?

oomnia replaces multiple systems with one interface, lowering manual entry, reducing query load, and simplifying workflows for sites managing complex oncology protocols.

Does oomnia support global, multi‑center oncology trials?

Yes. oomnia provides unified oversight across regions and vendors, helping sponsors manage variability in site readiness, technology adoption, and operational performance.

Is oomnia compliant with key regulations for oncology trials?

Yes. oomnia adheres to 21 CFR Part 11, ICH E6(R3), and CDISC standards, and supports regulatory submissions for FDA, EMA, and global authorities.

Can oomnia integrate imaging and biomarker data used in oncology research?

oomnia seamlessly connects imaging feeds from central reading centers with laboratory and biomarker streams, creating a consolidated view of clinical outcomes and molecular data.

How does a unified CRIS accelerate oncology trial timelines?

A unified clinical research information system (CRIS) removes data silos, automates data flow, and reduces reconciliation time, helping sponsors accelerate study startup, shorten time to first patient in (FPI), and achieve faster database lock.

Who benefits most from oomnia's oncology‑focused capabilities?

Biotech organizations, mid‑market pharma, oncology research teams, and CROs running adaptive, biomarker‑driven, or global oncology studies benefit most from oomnia's unified CRIS model.

Looking to advance oncology studies with greater efficiency and clarity?